Clinical Trials Logo

Corneal Diseases clinical trials

View clinical trials related to Corneal Diseases.

Filter by:

NCT ID: NCT05045053 Recruiting - Corneal Disease Clinical Trials

Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

NCT ID: NCT05027295 Recruiting - Keratoconus Clinical Trials

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

Start date: July 30, 2021
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies. Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

NCT ID: NCT04905108 Recruiting - Keratoconus Clinical Trials

Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia

Start date: June 2, 2021
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection and scarring, faster visual recovery and improved patient comfort in the early postoperative healing period.

NCT ID: NCT04848740 Enrolling by invitation - Clinical trials for Progressive Disease of Corneae

Human Fresh Corneal Lenticule Implantation Criteria in Progressive Corneal Disease Using Relex-Smile

Relex-Smile
Start date: February 1, 2018
Phase: N/A
Study type: Interventional

Stroma is a fibrous, tough, transparent and the thickest layer of the corneae. The stroma is composed of organised collagen, which maintains transparency. Keratocytes are located between the lamella collagen fibers and secrete an extracellular matrix, which includes collagen, proteoglycan, crystalline proteins to maintain corneal transparency.

NCT ID: NCT04804592 Completed - Cornea Clinical Trials

Investigation in Corneal Sensation and Contact Lens Wear

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

The aim is to find out more about how corneal sensory fibres react to different types of stimuli (liquid / tactile / nylon thread) and how this can be consciously perceived by the individual. Is it possible to generate a stimulus that delivers a repeatable and reliable response within a useful stimulus force range which allows an interpretation / evaluation of normal / expected activity of superficial nerve fibres in the cornea? The study group will be divided into three groups of individuals: two groups with different types of contact lenses (CL) and one without CL, as sensitivity changes are thought to occur with CL wear. A very interesting research question is to find out, if such sensitivity differences can be detected with the nature of the stimuli applied in this study.

NCT ID: NCT04773431 Completed - Limbus Corneae Clinical Trials

Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency

Start date: January 31, 2020
Phase: Phase 1
Study type: Interventional

Clinical Study Objective: To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency Study Method: Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.

NCT ID: NCT04737928 Completed - Clinical trials for Glaucoma, Primary Open Angle

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Start date: April 2, 2018
Phase: N/A
Study type: Interventional

The objective of this study was to investigate the improving effect of corneal disorder in primary open-angle glaucoma and ocular hypertension patients, when switched from the 0.005% latanoprost ophthalmic solution (one drop at a time, once daily) to the 0.0015% tafluprost ophthalmic solution (one drop at a time, once daily). Efficacy also was investigated.

NCT ID: NCT04734158 Active, not recruiting - Clinical trials for Cornea Epithelial Mapping

CORNEAL EPITHELIAL MAPPING IN DIABETICS

Start date: August 12, 2019
Phase:
Study type: Observational

The corneal epithelium is the outermost layer that covers the front of the eye; it not only functions as a barrier that blocks the passage of foreign material, but also plays an important role in maintaining high optical quality. The stem cells in the basal layer of the limbal epithelium hold a physiological significance in the renewal and metabolism of corneal epithelium, particularly under stressful situations.

NCT ID: NCT04668924 Active, not recruiting - Keratoconus Clinical Trials

Epi-on PiXL for the Treatment of Progressive Keratoconus.

Start date: March 20, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and postoperative ocular discomfort by individually customized Photorefractive intrastromal crosslinking (PiXL) without epithelium debridement in high oxygen environment (Epi-on) for progressive Keratoconus.

NCT ID: NCT04485858 Terminated - Corneal Disease Clinical Trials

First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness

Start date: January 3, 2021
Phase: N/A
Study type: Interventional

Prospective, open label, single arm, First in Human (FIH) clinical study to assess safety and efficacy of the CorNeat Keratoprosthesis, a synthetic cornea, for the treatment of corneal blindness